New asthma drug aims to slash severe attacks in Hard-to-Treat patients
NCT ID NCT06653322
First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests an experimental drug called SHR-1703 in 400 people aged 12 and older with eosinophilic asthma, a type often hard to control. Participants must already use daily inhaled steroids and another asthma medication. The goal is to see if the drug can reduce the number of asthma attacks over about 48 weeks compared to a placebo. The drug is given as an injection and aims to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA WITH EOSINOPHILIC PHENOTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China School of Medicine West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact
Conditions
Explore the condition pages connected to this study.